The AstraZeneca PLC ADR AZN advanced 2.74% to $72.44 Friday, on what proved to be an all-around positive trading session for ...

Cell therapy is considered by some as the next frontier in cancer treatment, engineering patients' own immune systems to attack cancer. Soon, Maryland will be home to one of the largest facilities ...

The AstraZeneca PLC ADR AZN advanced 1.52% to $69.55 Thursday, on what proved to be an all-around positive trading session ...

Pioneering a first-in-class drug-targeting approach that leverages hormone analogues to deliver small-molecule neuroplasticity modulators directly to the brain's appetite control centersFinancing ...

AstraZeneca CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on ...

Rare Disease Revenue: $2 billion, stable year-on-year. AstraZeneca PLC (NASDAQ:AZN) reported a strong start to 2025 with a 10% increase in total revenue, driven by demand for innovative medicines.

CAMBRIDGE, Britain (AP) — CAMBRIDGE, Britain (AP) — Astrazeneca PLC (AZN) on Tuesday reported first-quarter profit of $2.92 billion. On a per-share basis, the Cambridge, Britain-based company ...

Rare Disease Revenue: $2 billion, stable year-on-year. AstraZeneca PLC (NASDAQ:AZN) reported a strong start to 2025 with a 10% increase in total revenue, driven by demand for innovative medicines.

Pioneering a first-in-class drug-targeting approach that leverages hormone analogues to deliver small-molecule ...